-
Something wrong with this record ?
Current Advances in Allosteric Modulation of Muscarinic Receptors
J. Jakubik, EE. El-Fakahany
Language English Country Switzerland
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
Grant support
19-05318S
Grantová Agentura České Republiky - International
RVO:67985823
Akademie věd České Republiky - International
NLK
Directory of Open Access Journals
from 2011
PubMed Central
from 2011
Europe PubMed Central
from 2011
ProQuest Central
from 2011-01-01
Open Access Digital Library
from 2011-01-01
Open Access Digital Library
from 2011-01-01
Health & Medicine (ProQuest)
from 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2011
PubMed
32085536
DOI
10.3390/biom10020325
Knihovny.cz E-resources
- MeSH
- Muscarinic Agonists metabolism MeSH
- Allosteric Regulation physiology MeSH
- Muscarinic Antagonists metabolism MeSH
- Humans MeSH
- Ligands MeSH
- Receptors, Muscarinic metabolism physiology MeSH
- Receptors, G-Protein-Coupled MeSH
- Binding Sites MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
Allosteric modulators are ligands that bind to a site on the receptor that is spatially separated from the orthosteric binding site for the endogenous neurotransmitter. Allosteric modulators modulate the binding affinity, potency, and efficacy of orthosteric ligands. Muscarinic acetylcholine receptors are prototypical allosterically-modulated G-protein-coupled receptors. They are a potential therapeutic target for the treatment of psychiatric, neurologic, and internal diseases like schizophrenia, Alzheimer's disease, Huntington disease, type 2 diabetes, or chronic pulmonary obstruction. Here, we reviewed the progress made during the last decade in our understanding of their mechanisms of binding, allosteric modulation, and in vivo actions in order to understand the translational impact of studying this important class of pharmacological agents. We overviewed newly developed allosteric modulators of muscarinic receptors as well as new spin-off ideas like bitopic ligands combining allosteric and orthosteric moieties and photo-switchable ligands based on bitopic agents.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21012855
- 003
- CZ-PrNML
- 005
- 20210507101641.0
- 007
- ta
- 008
- 210420s2020 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/biom10020325 $2 doi
- 035 __
- $a (PubMed)32085536
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Jakubik, Jan $u Department of Neurochemistry, Institute of Physiology CAS, 142 20 Prague, Czech Republic
- 245 10
- $a Current Advances in Allosteric Modulation of Muscarinic Receptors / $c J. Jakubik, EE. El-Fakahany
- 520 9_
- $a Allosteric modulators are ligands that bind to a site on the receptor that is spatially separated from the orthosteric binding site for the endogenous neurotransmitter. Allosteric modulators modulate the binding affinity, potency, and efficacy of orthosteric ligands. Muscarinic acetylcholine receptors are prototypical allosterically-modulated G-protein-coupled receptors. They are a potential therapeutic target for the treatment of psychiatric, neurologic, and internal diseases like schizophrenia, Alzheimer's disease, Huntington disease, type 2 diabetes, or chronic pulmonary obstruction. Here, we reviewed the progress made during the last decade in our understanding of their mechanisms of binding, allosteric modulation, and in vivo actions in order to understand the translational impact of studying this important class of pharmacological agents. We overviewed newly developed allosteric modulators of muscarinic receptors as well as new spin-off ideas like bitopic ligands combining allosteric and orthosteric moieties and photo-switchable ligands based on bitopic agents.
- 650 _2
- $a alosterická regulace $x fyziologie $7 D000494
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a vazebná místa $7 D001665
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ligandy $7 D008024
- 650 _2
- $a agonisté muskarinových receptorů $x metabolismus $7 D018721
- 650 _2
- $a antagonisté muskarinových receptorů $x metabolismus $7 D018727
- 650 _2
- $a receptory spřažené s G-proteiny $7 D043562
- 650 _2
- $a receptory muskarinové $x metabolismus $x fyziologie $7 D011976
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a El-Fakahany, Esam E $u Department of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, Minneapolis, MN 55455, USA
- 773 0_
- $w MED00188737 $t Biomolecules $x 2218-273X $g Roč. 10, č. 2 (2020)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32085536 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210420 $b ABA008
- 991 __
- $a 20210507101641 $b ABA008
- 999 __
- $a ok $b bmc $g 1651099 $s 1133234
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 10 $c 2 $e 20200218 $i 2218-273X $m Biomolecules $n Biomolecules $x MED00188737
- GRA __
- $a 19-05318S $p Grantová Agentura České Republiky $2 International
- GRA __
- $a RVO:67985823 $p Akademie věd České Republiky $2 International
- LZP __
- $a Pubmed-20210420